Aurinia Pharmaceuticals Set to Attend Major Healthcare Conference

Author: Addison Perry Updated: 09-14-2024 06:37 AM

Aurinia Pharmaceuticals at Upcoming Healthcare Conference

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) has announced its participation in the anticipated 2024 Cantor Fitzgerald Global Healthcare Conference. This notable event will take place in New York City from September 17 to September 19.

Engagement and Investor Interaction

The management team at Aurinia is eager to engage with investors through a series of one-on-one meetings. Additionally, the Company will take part in an insightful fireside chat, which is scheduled for Tuesday, September 17, at 3:05 PM EDT. This session aims to facilitate meaningful dialogue between Aurinia's leadership and its investors.

Live Webcast Information

For those unable to attend in person, a live webcast of the fireside chat will be available on the Investor section of Aurinia's official website. This allows a broader audience to participate and stay informed about the Company's updates and insights.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals is on a mission to provide innovative treatments for patients grappling with autoimmune diseases, who often face significant unmet medical needs. The Company's flagship product is LUPKYNIS® (voclosporin), which made history as the first FDA-approved oral treatment focused specifically on adult patients suffering from active lupus nephritis.

Developments in Autoimmune Disease Treatments

Today, Aurinia is not resting on its laurels; it is actively working on AUR200, a novel therapy that has the potential to be a best-in-class option for autoimmune diseases. This innovative treatment is designed to engage both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand), which could provide new hope to those affected.

Future Prospects and Innovations

As Aurinia Pharmaceuticals continues to expand its pipeline and enhance its therapeutic offerings, the upcoming conference serves as a key platform for sharing its vision and progress with stakeholders. The interaction between Aurinia management and investors at this event is poised to fuel further interest in the Company's innovative approaches and relay its commitment to advancing treatment options.

Frequently Asked Questions

What is the purpose of the 2024 Cantor Fitzgerald Global Healthcare Conference?

The conference serves as a platform for healthcare companies, like Aurinia, to engage with investors and discuss their latest developments and strategies.

What is Aurinia's flagship product?

Aurinia's leading product is LUPKYNIS® (voclosporin), an FDA-approved oral therapy for lupus nephritis.

When will Aurinia present at the conference?

Aurinia's management will participate in a fireside chat on September 17, at 3:05 PM EDT.

How can I listen to the webcast of the presentation?

The webcast can be accessed through the Investor section of Aurinia's official website for those unable to attend in person.

What are the future prospects for Aurinia Pharmaceuticals?

Aurinia is focused on developing additional therapies, such as AUR200, to continue addressing unmet needs in the autoimmune disease space.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.